Search Strategy

<table>
<thead>
<tr>
<th>Project number</th>
<th>2012-01_GCP_Colon cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project name</td>
<td>Practice guideline Colon Cancer</td>
</tr>
<tr>
<td>Search question(s)</td>
<td>What is the current standard first line treatment for inoperable colorectal cancer?</td>
</tr>
</tbody>
</table>

**Structured search question(s) (PICO, SPICE, ECLIPSE, ..) and related keywords**

**P (patient)**
colorectal cancer (resectable solitary liver or lung metastases excluded)

**I (Intervention)**
Any chemotherapy and/or targeted therapy

**C (comparison)**
Fluoropyrimidin-based chemotherapy + oxaliplatin or irinotecan +/- bevacizumab

**O (outcome)**
PFS, OS, Cost, AE, QoL

NB we prefer not to use the word ‘palliative’ as interpretation can be ambiguous and term is not essential for PICO

Conclusions will be presented in three subheadings:
- Sequential versus combined chemotherapy
- Infusional versus bolus versus oral fluoropyrimidines
- Other chemotherapy agents and targeted therapies

Not included in this PICO:
- HIPEC
- Neo-adjuvant/induction chemotherapy followed by surgery

<table>
<thead>
<tr>
<th>Date</th>
<th>17-10-2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Database</td>
<td>Medline via OVID</td>
</tr>
</tbody>
</table>

**Search Strategy**

1 exp Colorectal Neoplasms/ (135684)
2 (colo$ adj5 cancer$).tw. (79548)
3 (colo$ adj5 neoplas$).tw. (5371)
4 (colo$ adj5 carcin$).tw. (32861)
5 (colo$ adj5 tumo$).tw. (22615)
6 (colo$ adj5 metastas$).tw. (15596)
7 (colo$ adj5 malig$).tw. (4632)
8 1 or 2 or 3 or 4 or 5 or 6 or 7 (168714)
9 exp Neoplasm Metastasis/ (145146)
10 stage IV.mp. (12962)
11 advanced.ab. (212385)
12 metastas$.tw. (269300)
13 9 or 10 or 11 or 12 (518288)
14 8 and 13 (43542)
15 exp Drug Therapy/ (1002836)
16 Colorectal Neoplasms/dt, th [Drug Therapy, Therapy] (10816)
17 15 or 16 (1008302)
18 14 and 17 (11819)
19 exp animals/ not humans.sh. (3793849)
20 18 not 19 (11378)
21 limit 20 to yr="2006 -Current" (5227)
22 meta-analysis.mp, pt. or review.pt. or search:.tw. (1889673)
23 randomized controlled trial.pt. (338952)
24 controlled clinical trial.pt. (85368)
25 randomized.ab. (241738)
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>placebo.ab. (135435)</td>
</tr>
<tr>
<td>27</td>
<td>clinical trials as topic.sh. (162982)</td>
</tr>
<tr>
<td>28</td>
<td>randomly.ab. (173480)</td>
</tr>
<tr>
<td>29</td>
<td>trial.ti. (104393)</td>
</tr>
<tr>
<td>30</td>
<td>22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 (2564810)</td>
</tr>
<tr>
<td>31</td>
<td>21 and 30 (1850)</td>
</tr>
</tbody>
</table>

Note